250) = 0.007) compared with those with lower disease activity. |
251) possible role for EBV reactivation in SLE disease activity. |
252) with traits that confer resistance to the disease are needed. |
253) breast cancer and diagnosis of metastatic disease are possible, and are expected to |
254) affect many organ systems, lung and heart disease are the leading causes of death. |
255) mal defects, respiratory failure and lung disease are the leading causes of morbidit |
256) are thought to influence cardiometabolic disease development and individuals' diets |
257) that could potentially be used to predict disease development. |
258) isk of future diabetes and cardiovascular disease development. |
259) ody space-type IR-associated degenerative disease development. |
260) selective pressures related to infectious disease or an undefined role in primate ph |
261) , performance, recovery, and pain (due to disease or injuries). |
262) ies focused on patients' attitudes toward disease or lack of trust in health-care pr |
263) g helps identify symptoms associated with diseases or disease-driven disorders, whic |
264) rstanding of relevant variables affecting disease outcomes in the Indo-Caribbean pop |
265) erlying Juul-associated respiratory tract disease outcomes include response to oxida |
266) e interpretation of studies, standardized disease outcomes should be used to improve |
267) netic variants associated with health and disease outcomes. |
268) f anesthesia administration when studying disease processes associated with inflamma |
269) microglia may also provide insights into disease processes involving cerebellar dys |
270) hedding light on their involvement in the disease processes. |
271) y the role of IsoLGs in a wide variety of disease processes. |
272) Osteosarcoma is a challenging bone disease which is commonly associated with |
273) exaggerated immune response (inflammatory disease), which may prove detrimental to t |
274) f mitochondrial import machinery in heart disease, which deserves considerable atten |
275) s follows: (1) "general manifestations of disease," which included behavioral change |
276) e-related neurodegeneration and Alzheimer Disease (AD), and assess the potential of |
277) d cogniitve impairment (MCI), Alzheimer's disease (AD), and Parkinson's disease (PD) |
278) Alzheimer's disease (AD), the most common form of deme |
279) eased risk of non-diabetic chronic kidney disease (CKD) and in particular of HIV ass |
280) g KLM formation in various chronic kidney disease (CKD) models. |
281) BACKGROUNDAssessment of chronic kidney disease (CKD) risk after acute kidney inju |
282) ve and safe in patients with a stable low disease activity, although more (high-qual |
|